An interventional study of Psychosocial information, counseling, and support and Donepezil (Aricept) in Alzheimer Disease and Caregivers, sponsored by Pfizer. Completed at 3 sites in 3 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2007-05-07.
Sponsored by Pfizer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 5th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 1999, is one of 6 with no phase, and was the 14th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
101 studies in Alzheimer Disease by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 99 finished, 40 (40%) have results posted.
Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 13th largest by enrollment of the 94 interventional ones that give a count, is the only one that started in 1999, is one of 3 with no phase, and was the 13th registered.
Pfizer’s Alzheimer Disease studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 101 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?
This study is a single-blind prospective randomized trial with 150 patient/caregiver pairs (50 in each country). Eligibility criteria at baseline require that the primary caregiver is the spouse of the patient; the patient must have a diagnosis of AD, be in the in mild to moderate stage of dementia, be living with the caregiver, and be willing to take Donepezil (Aricept). These participants were randomly assigned to one of two groups: in one group, the intervention consists of drug treatment for the patient plus psychosocial intervention for the caregiver; in the other group the intervention consists solely of drug treatment for the patient.
The intervention for the caregiver consists of 5 scheduled individual and family counseling sessions within 3 months of baseline, and unlimited consultations on request. Assessments were conducted every 3 months for the first year and every 6 months for a second year. There are 3 sources of data: an interview of the caregiver by an independent rater, an assessment of the patient, and a count of the amount of medication used. Thus we will be able to assess the effect of adding counseling to medication for the caregiver, for the patient, and on compliance with medication use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Caregiver: Changes in depression, measured with the Beck Depression Inventory
Time frame: every 3 months for the first year, and every 6 months for the second year
Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale
Time frame: every 3 months for the first year, and every 6 months for the second year
Patient: Changes in cognition measured by ADAS-cog
Time frame: every 3 months for the first year, and every 6 months for the second year
Patient: Changes in abilities with activities of daily living measured by ADCS-ADL
Time frame: every 3 months for the first year, and every 6 months for the second year
Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery
Time frame: every 3 months for the first year, and every 6 months for the second year
Patient: Time to nursing home placement
The record gives a start of Jul 1999 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil